An Observational Study to Evaluate the Major Bleeding Incidence Rate in Non-valvular Atrial Fibrillation Patients Treated with Rivaroxaban

Trial Profile

An Observational Study to Evaluate the Major Bleeding Incidence Rate in Non-valvular Atrial Fibrillation Patients Treated with Rivaroxaban

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 May 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Atrial fibrillation; Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PMSS
  • Most Recent Events

    • 20 May 2017 Results (n=57070) assessing major bleeding rates by age group and CHA2DS2-VASc scores, presented at the 2017 Annual Scientific Meeting of the American Geriatrics Society
    • 09 Dec 2016 Results (n= 44,793) comparing incidence of major bleeding with Rivaroxaban use among nonvalvular atrial fibrillation patients with or without diabetes mellitus, published in the American Journal of Cardiology.
    • 16 Nov 2016 Results (n=51,842) assessing major bleeding incidents in a heterogenous population of Nonvalvular Atrial Fibrillation was presented at the 89th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top